Your browser doesn't support javascript.
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-ß.
Simpson-Yap, Steve; Pirmani, Ashkan; De Brouwer, Edward; Peeters, Liesbet M; Geys, Lotte; Parciak, Tina; Helme, Anne; Hillert, Jan; Moreau, Yves; Edan, Gilles; Spelman, Tim; Sharmin, Sifat; McBurney, Robert; Schmidt, Hollie; Bergmann, Arnfin; Braune, Stefan; Stahmann, Alexander; Middleton, Rodden; Salter, Amber; Bebo, Bruce; van der Walt, Anneke; Butzkueven, Helmut; Ozakbas, Serkan; Karabudak, Rana; Boz, Cavit; Alroughani, Raed; Rojas, Juan I; van der Mei, Ingrid; Sciascia do Olival, Guilherme; Magyari, Melinda; Alonso, Ricardo; Nicholas, Richard; Chertcoff, Anibal; Zabalza, Ana; Arrambide, Georgina; Nag, Nupur; Descamps, Annabel; Costers, Lars; Dobson, Ruth; Miller, Aleisha; Rodrigues, Paulo; Prckovska, Vesna; Comi, Giancarlo; Kalincik, Tomas.
  • Simpson-Yap S; CORe, Department of Medicine, The University of Melbourne, Australia; Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Australia; Menzies Institute for Medical Research, University of Tasmania, Australia. Electronic address: steve.simpsonyap@un
  • Pirmani A; University MS Center, (UMSC) Hasselt/Pelt, Belgium; Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium; Biomedical Research Institute (BIOMED), Hasselt University, Agoralaan Building C, 3590 Diepenbeek, Belgium; Data Science Institute (DSI), Hasselt University, Agora
  • De Brouwer E; ESAT-STADIUS, KU Leuven, Belgium.
  • Peeters LM; University MS Center, (UMSC) Hasselt/Pelt, Belgium; Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium; Biomedical Research Institute (BIOMED), Hasselt University, Agoralaan Building C, 3590 Diepenbeek, Belgium; Data Science Institute (DSI), Hasselt University, Agora
  • Geys L; Biomedical Research Institute (BIOMED), Hasselt University, Agoralaan Building C, 3590 Diepenbeek, Belgium; Data Science Institute (DSI), Hasselt University, Agoralaan Building D, 3590, Diepenbeek, Belgium.
  • Parciak T; University MS Center, (UMSC) Hasselt/Pelt, Belgium; Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium; Biomedical Research Institute (BIOMED), Hasselt University, Agoralaan Building C, 3590 Diepenbeek, Belgium; Data Science Institute (DSI), Hasselt University, Agora
  • Helme A; MS International Federation, United Kingdom.
  • Hillert J; Department of Clinical Neuroscience, Swedish MS Registry, Sweden; Karolinska Institutet, Sweden.
  • Moreau Y; ESAT-STADIUS, KU Leuven, Belgium.
  • Edan G; Department of Neurology, CHU Pontchaillou, France.
  • Spelman T; Department of Clinical Neuroscience, Swedish MS Registry, Sweden; Karolinska Institutet, Sweden.
  • Sharmin S; CORe, Department of Medicine, The University of Melbourne, Australia.
  • McBurney R; iConquerMS People-Powered Research Network, Accelerated Cure Project for MS, United States of America.
  • Schmidt H; iConquerMS People-Powered Research Network, Accelerated Cure Project for MS, United States of America.
  • Bergmann A; NeuroTransData Study Group, NeuroTransData, Germany.
  • Braune S; NeuroTransData Study Group, NeuroTransData, Germany.
  • Stahmann A; German MS-Register by the National MS Society, MS Forschungs- und Projektentwicklungs-gGmbH, Germany.
  • Middleton R; UK MS Register, Swansea University, United Kingdom.
  • Salter A; COViMS, United States of America; Division of Biostatistics, Washington University in St Louis, United States of America.
  • Bebo B; COViMS, United States of America.
  • van der Walt A; Department of Neuroscience, Central Clinical School, Monash University, Australia.
  • Butzkueven H; Department of Neuroscience, Central Clinical School, Monash University, Australia.
  • Ozakbas S; Amiri Hospital, Kuwait.
  • Karabudak R; Department of Neurology, University of Hacettepe, Turkey.
  • Boz C; Department of Neurology, Karadeniz Technical University, Turkey.
  • Alroughani R; Dokuz Eylul University, Turkey.
  • Rojas JI; Neurology Department, Hospital Universitario de CEMIC, Argentina; RELACOEM, Argentina.
  • van der Mei I; The Australian MS Longitudinal Study, Menzies Institute for Medical Research, University of Tasmania, Australia.
  • Sciascia do Olival G; ABEM - Brazilian MS Patients Association, Brazil.
  • Magyari M; The Danish Multiple Sclerosis Registry, Departement of Neurology, University Hospital Rigshospitalet, Denmark.
  • Alonso R; RELACOEM, Argentina; Multiple Sclerosis University Center, Ramos Mejia Hospital - EMA, Argentina.
  • Nicholas R; UK MS Register, Swansea University, United Kingdom; Imperial College London, United Kingdom; Swansea University, United Kingdom.
  • Chertcoff A; MS and Demyelinating Diseases. Hospital Británico de Buenos Aires, EMA, Argentina.
  • Zabalza A; Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona, Spain.
  • Arrambide G; Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona, Spain.
  • Nag N; Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Australia.
  • Descamps A; icometrix, Belgium.
  • Costers L; icometrix, Belgium.
  • Dobson R; Queen Mary University London, United Kingdom.
  • Miller A; Imperial College London, United Kingdom.
  • Rodrigues P; QMENTA, Inc., Spain.
  • Prckovska V; QMENTA, Inc., Spain.
  • Comi G; Casa di Cura del Policlinico and Università Vita Salute San Raffaele, Italy.
  • Kalincik T; CORe, Department of Medicine, The University of Melbourne, Australia; MS Centre, Department of Neurology, Royal Melbourne Hospital, Australia.
Mult Scler Relat Disord ; 66: 104072, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2015867
ABSTRACT

BACKGROUND:

Interferon-ß, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.

RESULTS:

Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.

CONCLUSIONS:

In comparison to other DMTs, we did not find evidence of protective effects of interferon-ß on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-ß. This study does not support the use of interferon-ß as a treatment to reduce COVID-19 severity in MS.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / COVID-19 / Multiple Sclerosis Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / COVID-19 / Multiple Sclerosis Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article